ATE390422T1 - Quinazolin-derivate für die behandling von krebs - Google Patents

Quinazolin-derivate für die behandling von krebs

Info

Publication number
ATE390422T1
ATE390422T1 AT04727325T AT04727325T ATE390422T1 AT E390422 T1 ATE390422 T1 AT E390422T1 AT 04727325 T AT04727325 T AT 04727325T AT 04727325 T AT04727325 T AT 04727325T AT E390422 T1 ATE390422 T1 AT E390422T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
AT04727325T
Other languages
English (en)
Inventor
Nicola Heron
Georges Pasquet
Andrew Mortlock
Frederic Jung
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE390422T1 publication Critical patent/ATE390422T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04727325T 2003-04-16 2004-04-14 Quinazolin-derivate für die behandling von krebs ATE390422T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03290951 2003-04-16

Publications (1)

Publication Number Publication Date
ATE390422T1 true ATE390422T1 (de) 2008-04-15

Family

ID=33305809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727325T ATE390422T1 (de) 2003-04-16 2004-04-14 Quinazolin-derivate für die behandling von krebs

Country Status (23)

Country Link
US (1) US7691867B2 (de)
EP (1) EP1613619B1 (de)
JP (1) JP4709139B2 (de)
KR (1) KR20060003351A (de)
CN (1) CN1809557B (de)
AR (1) AR043875A1 (de)
AT (1) ATE390422T1 (de)
AU (1) AU2004232527A1 (de)
BR (1) BRPI0409427A (de)
CA (1) CA2522079A1 (de)
CL (1) CL2004000797A1 (de)
CO (1) CO5640037A2 (de)
DE (1) DE602004012725T2 (de)
ES (1) ES2301981T3 (de)
HK (1) HK1086573A1 (de)
IS (1) IS8125A (de)
MX (1) MXPA05011076A (de)
NO (1) NO20054842L (de)
RU (1) RU2005135337A (de)
TW (1) TW200510392A (de)
UY (1) UY28271A1 (de)
WO (1) WO2004094410A1 (de)
ZA (1) ZA200508372B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
DE60315892T2 (de) * 2002-12-24 2008-08-14 Astrazeneca Ab Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DE602004015108D1 (de) * 2003-06-02 2008-08-28 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
AU2005239878B9 (en) 2004-05-06 2010-01-07 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
WO2006040526A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives for use against cancer
JP4237242B2 (ja) 2004-10-12 2009-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2008515960A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0517734A (pt) 2004-11-17 2008-10-21 Korea Res Inst Chem Tech derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina
EP1888572A1 (de) * 2005-05-28 2008-02-20 AstraZeneca AB Chinazoline und ihre verwendung als aurorakinaseinhibitoren
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
JP2009508922A (ja) * 2005-09-22 2009-03-05 アストラゼネカ アクチボラグ ４−アミノピラゾール誘導体の製造方法
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
JP2009528335A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN103382158B (zh) * 2013-07-29 2015-11-18 张家港市大伟助剂有限公司 一种2-环戊基氨基乙醇的制备方法
US9951044B2 (en) 2013-09-19 2018-04-24 Pierre Fabre Medicament Quinazoline derivatives and their use as DNA methyltransferase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
AU7340096A (en) * 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
BR0014116A (pt) * 1999-09-21 2002-05-21 Astrazeneca Ab Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
PL360439A1 (en) * 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
TW200420542A (en) * 2002-08-23 2004-10-16 Kirin Brewery A compound having TGF β inhibition activity and a medicinal composition containing the same
ATE412657T1 (de) 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
AU2003290322A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Quinazoline compounds
DE60315892T2 (de) * 2002-12-24 2008-08-14 Astrazeneca Ab Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DE602004015108D1 (de) * 2003-06-02 2008-08-28 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AR043875A1 (es) 2005-08-17
HK1086573A1 (en) 2006-09-22
ZA200508372B (en) 2007-04-25
DE602004012725D1 (de) 2008-05-08
KR20060003351A (ko) 2006-01-10
CL2004000797A1 (es) 2005-05-27
NO20054842L (no) 2005-11-08
BRPI0409427A (pt) 2006-04-18
EP1613619B1 (de) 2008-03-26
RU2005135337A (ru) 2006-06-10
TW200510392A (en) 2005-03-16
ES2301981T3 (es) 2008-07-01
JP4709139B2 (ja) 2011-06-22
EP1613619A1 (de) 2006-01-11
CN1809557A (zh) 2006-07-26
UY28271A1 (es) 2004-11-30
IS8125A (is) 2005-11-11
US20060270692A1 (en) 2006-11-30
JP2006523660A (ja) 2006-10-19
CA2522079A1 (en) 2004-11-04
MXPA05011076A (es) 2006-01-24
CO5640037A2 (es) 2006-05-31
US7691867B2 (en) 2010-04-06
AU2004232527A1 (en) 2004-11-04
DE602004012725T2 (de) 2009-04-16
WO2004094410A1 (en) 2004-11-04
CN1809557B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
ATE390422T1 (de) Quinazolin-derivate für die behandling von krebs
NL1029763A1 (nl) Bereiding van gesubstitueerde chinazolinen.
DE602004022180D1 (de) Chinazolinderivate
DE602004004553D1 (de) Chinazolinderivate
IS7362A (is) Kínasólín efnasambönd
DK1847539T3 (da) Quinazolin-derivater
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NO20055459D0 (no) Prosesser
NO20054967D0 (no) Ammoniakk oksidasjonsprosess
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE372674T1 (de) N-arylhydrazonderivate für die saatgutbehandlung
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1678085T3 (da) Fluidbehandlingsindretning
ATE366242T1 (de) 5-substituierte chinazolinonderivate
NO20063114L (no) Enoxaparin for behandling av cancer
NO20055449D0 (no) Fremgangsmate for diagnostisering av behandling av kreft
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
ITVR20030088A1 (it) Procedimento per la realizzazione di fasce anti-implosione per cinescopi
NO20042850L (no) Kreftbehandling
ATE520402T1 (de) Anti-egfr-antikörper und vegfr-inhibitoren umfassende kombinationen für die behandlung von krebs
DK1824975T3 (da) LNA Oligonukleotider og behandlingen af cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties